FDA Releases Two Draft Guidance Documents to Advise Manufacturers on Post COVID-19 Protocol
During the COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) felt pressured to expeditiously authorize new medical devices that could protect the public. Medical equipment such as diagnostic tests, masks, gowns, gloves, respirators, ventilators and ventilator accessories, as well as sanitizers were in short supply. This led many manufacturers to step up and provide the public with new devices. These devices required expedient clearance for marketing. To meet these challenges, FDA created two novel pathways to approval and clearance – Emergency Use Authorization (EUA) and Enforcement Policies. Manufacturers utilized these pathways for lawful marketing of their devices. Although we are not out of the pandemic yet, FDA has signaled an end to these special rules by releasing two new guidance documents on December 22, 2021. In these draft guidance documents, FDA’s Center for Devices and Radiological Health (CDRH) spells out the transition that will be occurring soon.
The termination of EUAs and enforcement policies means that manufacturers that used either of these two pathways will need to secure authorization or approval of their devices within 180 days. The “clock” starts on the 180-day deadline differently depending on the particular pathway used by the manufacturer during the pandemic. (See the guidance documents, here [download 1] and here [download 2], for details on the 180-day requirement.) FDA also announced that it will hold a webinar on February 22, 2022 to explain the new guidance and how the transition away from the emergency measures will occur. FDA has set a deadline of March 23, 2022 for interested parties to submit comments, here https://www.regulations.gov/, which will allow FDA to review and evaluate the potential impact of this transition on manufacturers and distributors.
>It will be important for manufacturers to determine when their 180-day timer commences and what avenues are available for approval to avoid potential enforcement actions and recalls. Additionally, it is important to note that products that are marketed without the appropriate FDA clearance or approval can be extremely difficult to defend in products liability actions, providing another reason to ensure regulatory compliance. Manufactures should begin to confer with counsel regarding submission of applications to FDA through traditional approval and market clearance pathways. Per the guidance documents, these actions should take place before the last phase of the triphasic transition.
For more information on what will happen to products brought to market under pandemic regulatory pathways, please see “Emergency Use Authorization Be Aware Be Prepared,” a webinar Medmarc produced on this topic, which was presented by Jianlin Song, Esq. on July 27, 2021 and which is accessible here.
How Medmarc Can Help
Life sciences and medical technology companies face complex and evolving risks throughout the product lifecycle. Medmarc provides specialized life sciences insurance, medical device insurance, products liability coverage, and risk management expertise to address the unique exposures of the industry. From emerging technologies and clinical trials to products on the market, Medmarc combines decades of life sciences experience with specialized industry knowledge and insurance solutions.
Explore Medmarc's insurance solutions to learn more about our capabilities, and talk with your insurance broker about your organization’s evolving risks and insurance considerations.
Phone: 888-633-6272
Copyright © 2026 - Medmarc
Related Articles
Three Years Since the Draft Guidance was Released, FDA Issues their Final Guidance Document on Clinical Decision Support Software
On September 28, 2022, FDA released their 26-page final guidance document titled, “Clinical...FDA Draft Guidance For Predetermined Change Control Plans (PCCPs) for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions
Since the publication of the Artificial Intelligence/Machine Learning (AI/ML)-Based Software...Medmarc is a proud member of TDC Specialty. TDC Specialty is the marketing name for the specialty insurance operations and services of The Doctors Company and its subsidiaries and affiliated companies, including TDC Specialty Underwriters, Inc., TDC Specialty Insurance Company, TDC National Assurance Company, Healthcare Risk Advisors, Inc., Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, and Medmarc Casualty Insurance Company. All products and services are written or provided by subsidiaries or affiliates of The Doctors Company. The Doctors Company does not underwrite excess and surplus lines insurance. Certain coverages may be provided through surplus lines insurance subsidiaries of The Doctors Company through licensed surplus lines brokers. Coverages may be underwritten by TDC Specialty Insurance Company, TDC National Assurance Company, Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, or Medmarc Casualty Insurance Company. Product summaries are for informational purposes only. Coverage is subject to the language of the policy as actually issued. Coverage, policy terms, and availability may vary by state.
TDC Specialty Underwriters, Inc., is based and domiciled in Connecticut; in California d/b/a Insurance City Solutions (license #0L85833) and in New York, d/b/a TDC Specialty Underwriters Services. Healthcare Risk Advisors, Inc., is based and domiciled in New York.
